Formoterol/fluticasone propionate

Drug Profile

Formoterol/fluticasone propionate

Alternative Names: Abriff; Fluticasone propionate/formoterol fumarate; Fluticasone/formoterol; Flutiform; flutiform K-Haler; Flutiformo; Flutiform™ HFA-MDI; Formoterol fumarate/fluticasone propionate; Iffeza; KRP-108

Latest Information Update: 21 Dec 2016

Price : $50

At a glance

  • Originator SkyePharma PLC
  • Developer Kyorin Pharmaceutical; Mundipharma International; Mundipharma Research; SkyePharma PLC; Vectura
  • Class Antiallergics; Antiasthmatics; Ethanolamines; Glucocorticoids; Small molecules
  • Mechanism of Action Beta 2 adrenergic receptor agonists; Glucocorticoid receptor agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No
  • Available For Licensing Yes - Asthma; Asthma

Highest Development Phases

  • Marketed Asthma
  • Phase III Chronic obstructive pulmonary disease

Most Recent Events

  • 23 Nov 2016 Mundipharma plans a clinical trial for Asthma in China
  • 07 Nov 2016 Mundipharma terminates a phase II/III trial in Asthma and Chronic obstructive pulmonary disease in Slovakia and Poland due to enrolment issues (NCT02693769) (EudraCT2015-002046-31)
  • 30 Aug 2016 Mundipharma completes a phase III trial in Chronic pulmonary obstructive disease in Hungary, South Korea, Latvia, Lithuania, Macedonia, Poland, romania, Russia, Slovakia, South Africa, Spain, Ukraine, Bulgaria, Germany and United Kingdom (NCT01946620)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top